Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161360 | 0.85 | MAPT (0.46) | MAPTPKMTACR1 | |
| SCHEMBL5158964 | 0.74 | MAPT (0.39) | MAPTPKMTACR1 | |
| SCHEMBL5158315 | 0.74 | NPC1 (0.42) | MAPTPKMTACR1SMN1; SMN2LMNA | |
| SCHEMBL6481099 | 0.74 | MAPT (0.42) | MAPTPKMTACR1 | |
| SCHEMBL6493783 | 0.72 | GRM7 (0.42) | — | |
| SCHEMBL2796237 | 0.71 | HTT (0.54) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL29484110 | 0.71 | HTT (0.54) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL29706163 | 0.71 | HTT (0.54) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2792830 | 0.71 | HTT (0.54) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL242244 | 0.71 | HTT (0.54) | SMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | MAPK1 1698/4885MAPK14 1765/4885MAPT 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.